NeuroBo Pharmaceuticals announced dosing of the first patient in the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, for the treatment of obesity. The company anticipates reporting top-line data from the SAD Part 1 during the third quarter of this year, and from the MAD Part 2 in the first quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRBO:
- NeuroBo Pharmaceuticals to sell 4.33M shares at $3.93 in private placement
- NeuroBo Pharmaceuticals’ DA-1726 demonstrates ‘superiority in weight loss’
- NeuroBo Pharmaceuticals Enhances Equity Plan and Elects Directors
- NeuroBo to report pre-clinical data on DA-1241 at EASL Congress 2024
- NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update